8 December 2025
Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology
Oslo, Norway, 8 December 2025 – Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been published in the respected peer-reviewed journal Gynecologic Oncology, under the title: “First experience with intraperitoneal 224Ra-labeled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer.“
“We are proud to announce that our article has been published in Gynecologic Oncology. This recognition underscores the importance of our research and validates our ongoing efforts. As our phase 2 study progresses in patients with peritoneal metastasis from ovarian cancer, we remain fully committed to advancing new treatment options to address this urgent medical need,” said Kari Myren, Chief Medical Officer at Oncoinvent.
The primary objectives of the phase 1 study were to evaluate the safety and tolerability of the alpha emitting therapy using 224Ra-labeled microparticles (Radspherin®) and to determine the recommended dose for subsequent clinical development. Initial experiences indicate that all dose levels were well tolerated, no dose limiting toxicity was observed during dose escalation and the highest dose of 7 MBq was selected as the recommended dose for the expansion phase. Alongside the now published 12-month data, Oncoinvent has also released topline 24-month follow-up data for the phase 1 study in ovarian cancer patients.
A randomized controlled phase 2 study is ongoing to evaluate the efficacy and safety of Radspherin® in patients with peritoneal metastasis from ovarian cancer. The primary aim is to compare progression-free survival (PFS) between two groups: those who receive Radspherin® following complete surgical resection after pre-operative chemotherapy, and those treated with pre-operative chemotherapy and surgery alone. Further details can be found at clinicaltrials.gov.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
